INTRODUCTION
============

Asthma is a heterogeneous, respiratory disease with various endotypes that combine clinical phenotypes with a distinct pathological mechanism.[@B1] To better understand the pathophysiology of asthma, studies have examined the functions of immune cells such as lymphocytes, mast cells, eosinophils and neutrophils in allergic inflammation, and targeted them for the development of novel therapeutics in asthmatics. Asthmatics with eosinophilic inflammation show favorable responses to corticosteroid therapy, while asthmatics with neutrophilic inflammation show poor responses to corticosteroid therapy.[@B2] A specific treatment targeting for a specific endotype of asthma has been generally recognized as the most effective therapy in asthmatics.[@B1][@B3]

There is increasing evidence of a pathologic role of neutrophil-mediated inflammation and clinical benefits of neutrophil-targeting therapies in asthma.[@B4][@B5] Neutrophilic asthma, which is defined by sputum neutrophil counts, shows distinct pathological features. Sputum neutrophil counts are associated with persistent airflow limitation and asthma severity in adult asthmatics.[@B6][@B7] Neutrophil-mediated airway inflammation in severe asthma (SA) persists despite treatment with high-dose glucocorticoids.[@B2] These findings strengthen the rationale for targeting neutrophils as an immunotherapeutic target for severe asthma. A number of\' anti-inflammatory therapeutics such as C-X-C Motif Chemokine Receptor 2 (CXCR2) antagonists and anti-interleukin (IL)-17 receptor alpha monoclonal antibodies have been examined in non-eosinophilic asthma[@B8][@B9]; however, they do not appear to have significant therapeutic effects on asthma. Therefore, neutrophils are still of primary importance in the therapeutic strategy for severe asthma. Nevertheless, there is little information on who would benefit the most from neutrophil-targeting therapy. In a recent study, aberrant neutrophil processes such as autophagy and the neutrophil extracellular DNA trap enhanced the inflammatory responses of human airway epithelial cells and eosinophils in severe asthma.[@B10][@B11] In addition, increased leukotriene B4 generation due to impaired granulocyte function was noted in patients with aspirin-exacerbated respiratory disease (AERD) along with a positive correlation with platelet-adherent neutrophils.[@B12]

Here, we evaluated the functional status of neutrophils in asthmatics using an *in vitro* stimulation model of human peripheral blood neutrophils (PBNs) by measuring reactive oxygen species (ROS) production, CD11b cell surface expression, and the release of IL-8 and granular enzyme matrix metallopeptidase (MMP)-9. Along with changes in lung function and airway hyperresponsiveness, we compared neutrophil functional status according to the phenotype of asthma. Considering the multicellular effect of sphingosine-1-phosphate (S1P) signaling in airway inflammation, we also investigated the potential therapeutic benefit of FTY720, a S1P functional antagonist.[@B13] S1P signaling is associated with airway responsiveness, bronchoconstriction and airway remodeling via the regulation of target cell proliferation in asthma.[@B14][@B15] Moreover, S1P can further enhance neutrophil activation (*i.e.*, Fcγ receptor-mediated calcium influx[@B16] and *N*-formyl-methionyl-leucyl-phenylalanine \[fMLP\]-induced ROS generation).[@B17] Therefore, we hypothesized that FTY720 is a potential target for neutrophilic inflammation in adult asthmatic patients.

MATERIALS AND METHODS
=====================

Materials
---------

S1P was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). FTY720 (2-amino-2-\[2-(4-octyl-phenyl)-ethyl\]-propane-1,3-diol hydrochloride), fMLP, lipopolysaccharides (LPSs) and ethylenediaminetetraacetic were obtained from Sigma-Aldrich (St. Louis, MO, USA). 2′,7′-dichloroflourescin diacetate (H2DCFDA) was purchased from ThermoFisher Scientific (Waltham, MA, USA).

Study subjects
--------------

This study enrolled 59 asthmatic patients (20 AERD, and 39 aspirin-tolerant asthma \[ATA\] patients) from Ajou University Hospital (Suwon, Korea). Written informed consent was obtained from each subject and the study was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-GEN-SMP-13--108). The clinical history and chest radiographs of all asthmatic patients were evaluated. Subjects underwent spirometry to record forced expiratory volume in 1 second (FEV1)% predicted value, forced vital capacity (FVC)% predicted value, FEV1/FVC and maximal mid-expiratory flow (MMEF)% predicted value. Asthma was diagnosed based on recurrent episodes of wheezing, dyspnea, cough and evidence of airway hyper-responsiveness to methacholine (a decrease in FEV1 \[%\] of 20% on methacholine challenge test \[PC20\]).[@B18] All of the subjects had been maintained on ICS and a long-acting β2 agonist to control their asthma symptoms according to the Global Initiative for Asthma guidelines.[@B19] The severity of asthma and control status were defined according to the International Guidelines of the European Respiratory Society/American Thoracic Society.[@B20] Aspirin hypersensitivity was identified using the L-lysine aspirin provocation test (Lys-ASA BPT).[@B21] A diagnosis of AERD was established based on 1) the clinical history of hyper-reactivity against aspirin or other nonsteroidal anti-inflammatory drugs and 2) the positive results to Lys-ASA BPT (a decrease in FEV1 \[%\] of more than 15% after the challenge). As a control group, asthmatic subjects who were able to tolerate to aspirin were classified as ATA. Subjects with comorbidities or using systemic corticosteroids, other immunosuppressants or biologics were excluded.

Atopy was identified as 1 or more positive reactions on skin prick test results.[@B22] Serum total immunoglobulin E was measured using the ImmunoCAP system (ThermoFisher Scientific), with the range of detection 2-5,000 kU/L. Neutrophil and eosinophil counts in sputum were evaluated as described in a previous study.[@B23]

Isolation of PBN from asthmatic patients
----------------------------------------

Peripheral blood from all study subjects was collected into BD vacutainer^®^ tubes containing acid citrate dextrose solution (BD Biosciences, Franklin Lakes, NJ, USA) and PBN isolation was processed within 2 hours after collection as described in a previous study.[@B10] PBNs were resuspended in RPMI-1640 medium supplemented with 2% heat-inactivated fetal bovine serum, penicillin (100 IU/mL) and streptomycin (50 µg/mL) (all were obtained from Gibco, Grand Island, NY, USA). Cell viability (\> 98%) was assessed using trypan blue exclusion assay (Sigma-Aldrich). Cell purity (\>95%) was assessed using flow cytometry based on CD11b expression.

*In vitro* PBN stimulation assay
--------------------------------

Freshly isolated PBNs (5 × 10^5^ cells/well) were stimulated with 1 µM fMLP (or 1 µM LPS) for 1 hour at 37°C under 5% CO~2~. To examine the inhibitory action of FTY720 on PBN activation, PBNs were primed with 1 µM FTY720 for 10 minutes at 37°C under 5% CO~2~ and then stimulated with fMLP (or LPS) for 1 hour.

Measurement of ROS in PBNs
--------------------------

The ROS-sensitive dye H2DCFDA was added to the PBNs at a final concentration of 10 µM for 30 minutes in the dark at 37°C under 5% CO~2~. A gate of the single PBNs was set and the DCF fluorescence intensity of PBNs was measured by flow cytometry using a BD FACSCanto II (BD Biosciences, East Rutherford, NJ, USA). To quantify the ROS production in PBNs, the mean fluorescence intensity (MFI) of the DCF signals from PBNs were recorded for statistical analysis.

Evaluation of CD11b expression on PBN
-------------------------------------

CD11b expression on PBNs was quantified by flow cytometric analysis. After stimulation, PBNs were stained with phycoerythrin-labeled anti-human CD11b (activation epitope) antibody (eBioscience Inc., San Diego, CA, USA) for 20 minutes, at room temperature. Cells were analyzed immediately by BD FACSCanto II (BD Bioscience) and at least 10,000 events were recorded for each condition. The CD11b^+^ cells were defined by comparing to the isotype control. Given the limited numbers of PBNs, we were only able to perform CD11b labeling on a limited number of subjects.

Measurement of inflammatory mediators
-------------------------------------

Cell supernatants were collected and stored at −20°C for later enzyme-linked immunosorbent assay (ELISA) analysis. IL-8 and MMP-9 levels were measured using ELISA, according to the manufacturer\'s instructions (R&D systems, Minneapolis, MN, USA).

Statistical analysis
--------------------

Statistical analysis was performed using SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.02 (GraphPad Software, San Diego, CA, USA). All analyses were performed at the 0.05 level, and 95% confidence intervals were two-sided intervals. Student\'s *t* test was used to compare the data for continuous variables; Pearson\'s χ^2^ or Fisher\'s exact tests were used for categorical variables. General linear regression analysis was performed to adjust for confounding factors, sex and age to compare ROS and cytokine levels between two groups (AERD vs. ATA, severe asthma vs. non-severe asthma). Paired *t* test was used to compare paired continuous variables. Pearson\'s correlation coefficient was used to identify the associations between continuous variables.

RESULTS
=======

Clinical characteristics of the study subjects
----------------------------------------------

The study enrolled 59 asthma patients. [Table 1](#T1){ref-type="table"} summarizes their clinical characteristics. The mean age of the asthmatic patients was 49.53 ± 14.36 years and 64.41% were female. Atopy was observed in 68.97% of the patients. Subjects were stratified by disease severity and aspirin hypersensitivity. Patients with severe asthma showed significantly reduced pulmonary functions; lower baseline levels of FEV1% predicted value, FVC % predicted value, and MMEF % predicted value (*P* \< 0.05 for all). The patients with AERD had a higher frequency of rhinosinusitis than those with ATA (77.78% vs. 50%, *P* = 0.044).

###### Clinical characteristics of the study subjects

![](aair-11-381-i001)

  Clinical characteristics             Asthma (n = 59)         SA (n = 9)        NSA (n = 50)      *P* value (SA vs. NSA)   AERD (n = 20)   ATA (n = 39)      *P* value (AERD vs. ATA)   
  ------------------------------------ ----------------------- ----------------- ----------------- ------------------------ --------------- ----------------- -------------------------- -----------
  Demographics                                                                                                                                                                           
                                       Sex (female), No. (%)   38/59 (64.41)     3/9 (33.33)       35/50 (70)               **0.044**       13/20 (65)        25/39 (64.1)               0.590
                                       Age (yr)                49.53 ± 14.36     56 ± 12.53        48.35 ± 14.47            0.143           53.85 ± 11.92     47.26 ± 15.15              0.076
                                       Atopy (presence, %)     40/58 (68.97)     5/9 (55.56)       35/49 (71.43)            0.282           10/19 (52.63)     30/39 (76.92)              0.059
                                       Total IgE               342.27 ± 352.41   413.78 ± 546.84   328.28 ± 307.65          0.660           297.11 ± 326.95   364.24 ± 366.46            0.512
  Pulmonary function                                                                                                                                                                     
                                       FEV1 (% predicted)      91.02 ± 13.89     78.38 ± 21.52     93.04 ± 11.31            **0.005**       89.33 ± 17.58     91.91 ± 11.67              0.506
                                       FVC (% predicted)       92.57 ± 11.97     84.64 ± 18.58     93.84 ± 10.26            **0.042**       92.81 ± 14.3      92.45 ± 10.75              0.914
                                       FEV1/FVC                82.45 ± 8.59      77.94 ± 12.64     83.17 ± 7.69             0.110           79.56 ± 9.3       83.98 ± 7.9                0.062
                                       MMEF (% predicted)      69.51 ± 23.5      52.03 ± 20.69     72.31 ± 22.87            **0.022**       66.6 ± 25.59      71.04 ± 22.52              0.498
                                       PC20 (mg/mL)            5.22 ± 7.28       3.72 ± 6.88       5.38 ± 7.38              0.633           3.74 ± 6.22       5.94 ± 7.73                0.312
  Sputum cell differential count (%)                                                                                                                                                     
                                       Eosinophils             32.78 ± 32.42     41 ± 38.01        31.75 ± 32.2             0.598           27.77 ± 34.11     35.61 ± 31.85              0.494
                                       Neutrophils             58.69 ± 32.81     57 ± 38.38        58.9 ± 32.75             0.915           65.83 ± 33.52     54.96 ± 32.55              0.360
  Relevant comorbidities, No. (%)                                                                                                                                                        
                                       Rhinosinusitis          33/56 (58.93)     7/9 (77.78)       26/47 (55.32)            0.190           14/18 (77.78)     19/38 (50)                 **0.044**
                                       Nasal polyps            15/20 (75)        1/1 (100)         14/19 (73.68)            0.750           9/12 (75)         6/8 (75)                   0.704

Asthma phenotypes and severity were defined as in the Materials and Methods sections. The continuous data are presented as the means ± standard deviation. The dichotomous data are presented as numbers (%). The data were analyzed with Student\'s *t* test and Pearson\'s χ^2^ test. The values in bold indicate significant *P* value.

SA, severe asthma; NSA, non-severe asthma; AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; IgE, immunoglobulin E; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PC20, a decrease in FEV1 (%) of 20% on methacholine challenge test.

Functional evaluation of neutrophil status using an *in vitro* model
--------------------------------------------------------------------

To examine the functional status of neutrophils in asthmatics, we isolated human PBNs, stimulated them with fMLP or LPS for 1 hour, and then measured biomarkers representing neutrophil functions (*i.e.*, ROS production and CD11b cell surface expression on PBNs, IL-8 \[a pro-inflammatory cytokine\] and MMP-9 \[a granular enzyme\] release). fMLP and LPS stimulation on PBNs significantly increased ROS production and CD11b, IL-8 and MMP-9 levels (*P* \< 0.05 for all, [Fig. 1](#F1){ref-type="fig"}). Furthermore, the fold induction of ROS production after fMLP stimulation as compared to baseline was significantly associated with decreased MMEF % (r = −0.309; *P* = 0.019), decreased FEV1/FVC ratio (r = −0.278; *P* = 0.036), and increased bronchial hyper-reactivity to methacholine (r = −0.302; *P* = 0.029) ([Fig. 2](#F2){ref-type="fig"}).

![*In vitro* PBN activation under fMLP or LPS stimulation. PBNs were isolated from asthmatics, stimulated under (A) fMLP stimulation or (B) LPS stimulation in 1 hour. The MFI of DCF fluorescence of PBNs and CD11b expression percentage were measured by flow cytometry; IL-8 and MMP-9 in the supernatants were measured by enzyme-linked immunosorbent assay. Data are presented as means ± standard deviation. *P* values were analyzed by paired *t*-test.\
fMLP, N-formyl-methionyl-leucyl-phenylalanine; LPS, lipopolysaccharide; PBN, peripheral blood neutrophil; IL, interleukin; MMP, matrix metallopeptidase; ROS, reactive oxygen species.](aair-11-381-g001){#F1}

![Correlations of PBN-derived ROS production with the severity of airway obstruction and bronchial hyper-reactivity. PBNs from asthmatics were stimulated with fMLP and measured for the DFC fluorescence intensity. Correlations of ROS and (A) FEV1/FVC; (B) MMEF (%) predicted values; (C) PC20. *P* values were analyzed by Pearson correlation coefficient analysis.\
FEV1, forced expiratory volume in 1 second; FEV1/FVC ratio, a ratio of forced expiratory volume in 1 second to forced volume vital; MMEF, maximal mid-expiratory flow; PC20 methacholine, methacholine provocative concentration causing a 20% drop in FEV1; ROS, reactive oxygen species; MFI, mean fluorescence intensity.](aair-11-381-g002){#F2}

Neutrophil functional status according to the phenotype of asthma
-----------------------------------------------------------------

Next, we stratified the patients according to the phenotype and then compared the functional status of neutrophils. ROS production with simulation was further increased in asthmatics as the symptoms got worse ([Table 2](#T2){ref-type="table"}). fMLP-induced ROS production in the severe asthma group was significantly higher than that in the non-severe asthma group (*P* = 0.011). AERD patients showed significantly higher ROS production stimulated by both fMLP and LPS than ATA patients (*P* \< 0.01 for all). Subjects with uncontrolled asthma had significantly increased ROS production under LPS stimulation compared to subjects with partly controlled or controlled asthma (*P* = 0.027, [Supplementary Table S1](#S1){ref-type="supplementary-material"}).

###### PBN-derived ROS production under stimulation according to the phenotype of asthma
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  Stimulation        SA (n = 9)   NSA (n = 49)          *P* value^\*^ (SA vs. NSA)   Asthma (n = 58)   AERD (n = 20)         ATA (n = 38)          *P* value^\*^ (AERD vs. ATA)   
  ------------------ ------------ --------------------- ---------------------------- ----------------- --------------------- --------------------- ------------------------------ --------------
  fMLP stimulation                                                                                                                                                                
                     Con          1,642.33 ± 1,673.77   1,292.9 ± 808.57             0.151             1,347.12 ± 979.81     2,031.85 ± 1,399.63   986.74 ± 293.6                 **\< 0.001**
                     fMLP         3,235.44 ± 2,868.46   2,059.61 ± 806.32            **0.011**         2,242.07 ± 1,373.59   3,073.9 ± 1,935.96    1,804.26 ± 641.18              **0.001**
                     fMLP + FTY   2,491 ± 1,947.11      1,699.79 ± 681.63            **0.030**         1,824.72 ± 1,008.1    2,433.11 ± 1,430.3    1,520.53 ± 507.75              **0.002**
  LPS stimulation                                                                                                                                                                 
                     Con          1,642.33 ± 1,673.77   1,292.9 ± 808.57             0.151             1,347.12 ± 979.81     2,031.85 ± 1,399.63   986.74 ± 293.6                 **\< 0.001**
                     LPS          2,541.38 ± 2,262.17   1,758.19 ± 897.58            0.100             1,883.5 ± 1,220.37    2,800.07 ± 1,696.19   1,527.06 ± 741.39              **0.002**
                     LPS + FTY    1,944.5 ± 1,969.66    1,498.95 ± 639.46            0.189             1,570.24 ± 961.04     2,329.07 ± 1,482.62   1,275.14 ± 395.82              **0.001**

Data are presented as means ± standard deviation of the mean fluorescence intensity values.

SA, severe asthma; NSA, non-severe asthma; AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; Con, mock-treated cells; fMLP, N-formyl-methionyl-leucyl-phenylalanine, LPS, lipopolysaccharide; FTY, FTY720.

^\*^*P* value was calculated by general linear regression analysis. The values in bold indicate significant *P* values.

Evaluation of the therapeutic potential of FTY720 using an *in vitro* model
---------------------------------------------------------------------------

To examine the clinical relevance of this *in vitro* PBN stimulation model for the evaluation of the therapeutic potential of FTY720, we compared the effects of FTY720 on the fMLP- (and LPS) stimulated neutrophil functions. ROS production and CD11b surface expression induced by fMLP or LPS stimulation were significantly decreased in the presence of FTY720 (*P* \< 0.05 for all, [Fig. 3](#F3){ref-type="fig"}). LPS-induced IL-8 and MMP-9 levels were also significantly decreased in the presence of FTY720 (*P* \< 0.05, [Fig. 3](#F3){ref-type="fig"}), while the inhibitory effect of FTY720 on fMLP-mediated IL-8 and MMP-9 release did not reach a statistical significance ([Fig. 3](#F3){ref-type="fig"}). To compare the clinical features of responders and non-responders to the FTY720 treatment, asthmatic patients were stratified by the reduction ratio of ROS production in the presence of FTY720. Responders were defined as patients who showed more than 10% ROS reduction after the FTY720 treatment. As shown in [Table 3](#T3){ref-type="table"}, the sputum neutrophil counts were significantly higher in responders than in non-responders (*P* = 0.004). There were no significant differences in % of FTY720 responders according to the phenotype of asthma such as aspirin hypersensitivity, the disease severity and the control status (*P* = 0.502; *P* = 1.000; *P* = 0.791, [Table 3](#T3){ref-type="table"}). However, degree of increment of ROS production under fMLP stimulation was significantly decreased with FTY720 treatment ([Supplementary Table S2](#S2){ref-type="supplementary-material"}).

![Inhibitory action of FTY720 on neutrophil activation in asthmatics. PBNs were isolated from asthmatics, treated with FTY720 and stimulated under (A) fMLP stimulation or (B) LPS stimulation in 1 hour. *P* values were analyzed by paired *t* test.\
fMLP, N-formyl-methionyl-leucyl-phenylalanine; LPS, lipopolysaccharide; PBN, peripheral blood neutrophil; IL, interleukin; MMP, matrix metallopeptidase; ROS, reactive oxygen species.](aair-11-381-g003){#F3}

###### Clinical characteristics of responders and non-responders to the FTY720 treatment
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  Clinical characteristics             Responders (n = 40)                         Non-responders (n = 17)   *P* value       
  ------------------------------------ ------------------------------------------- ------------------------- --------------- --------------
  Demographics                                                                                                               
                                       Sex (female), No. (%)                       30/40 (75)                8/17 (47.1)     0.043
                                       Age (yr)                                    48.7 ± 14.7               48.8 ± 14.6     0.979
                                       Atopy (presence, %)                         26/40 (65)                12/14 (85.7)    0.454
                                       Total IgE                                   337.3 ± 354.7             331.9 ± 362.1   0.960
  Pulmonary function                                                                                                         
                                       Baseline FEV1 (% predicted)                 91.5 ± 13.3               89.8 ± 16.2     0.678
                                       Baseline FVC (% predicted)                  93.2 ± 11.4               91.1 ± 14       0.557
                                       Baseline FEV1/FVC                           82.3 ± 7.6                83 ± 11.1       0.796
                                       PC20 (mg/mL, methacholine)                  5.2 ± 7.2                 5.5 ± 7.9       0.881
  Sputum cell differential count (%)                                                                                         
                                       Eosinophils                                 28.4 ± 32.4               47.1 ± 29.7     0.124
                                       Neutrophils                                 67.7 ± 29.7               33.4 ± 26.9     0.004
  Asthma phenotype                                                                                                           
                                       Aspirin hypersensitivity                                                              0.502
                                                                                   AERD                      13/37 (35.1)    6/17 (35.3)
                                                                                   ATA                       27/37 (73.0)    11/17 (64.7)
                                       Severity                                                                              1.000
                                                                                   SA                        6/40 (15.0)     3/17 (17.6)
                                                                                   NSA                       34/40 (85.0)    14/17 (82.4)
                                       Control status by GINA guideline, No. (%)                                             0.791
                                                                                   Controlled                20/40 (50.0)    8/17 (47.1)
                                                                                   Partly controlled         15/40 (37.5)    8/17 (47.1)
                                                                                   Uncontrolled              5/40 (12.5)     1/17 (5.9)

Responders were defined as patients who show ≥10% reactive oxygen species reduction in the presence of FTY720 under N-formyl-methionyl-leucyl-phenylalanine stimulation. Asthma control status and inflammatory subtype of asthma were defined as described in Materials and Methods section. The data are presented as means ± standard deviation for continuous variables and percentage for categorical variables. The data were analyzed with Student\'s *t*-test and Pearson\'s χ^2^ test.

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PC20, a decrease in FEV1 (%) of 20% on methacholine challenge test; AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; SA, severe asthma; NSA, non-severe asthma.

DISCUSSION
==========

Although the clinical relevance of neutrophilic inflammation to the phenotype of severe asthma is increasing, the functional status of neutrophils in asthmatic airway remains insufficiently understood. In the present study, we assessed the functional status of neutrophils using an *in vitro* PBN stimulation model along with clinical parameters of adult asthmatics and evaluated the therapeutic potential of FTY720 using an *in vitro* model.

Sputum neutrophil count allows for the evaluation of neutrophil numbers in the airway lumen and is associated with poor asthma control. [@B6][@B24] However, it\'s difficult to evaluate pre-activated or primed neutrophils in peripheral blood homing to the lungs and their contribution to exacerbating the airway inflammation. Consequently, we hypothesized that biomarkers of primed neutrophils in an *in vitro* model using PBNs of asthmatics would serve as an early read-out for assessing neutrophilic airway inflammation. Stimuli such as the neutrophil chemotactic factor fMLP and a bacterial endotoxin, LPS, can effectively induce ROS production in human PBNs.[@B25][@B26] ROS is a key signaling molecule that stimulates pro-inflammatory cytokine production and promotes allergic airway inflammation through airway smooth muscle contraction and bronchial hyperresponsiveness.[@B27][@B28][@B29] In the present study, ROS production under fMLP stimulation increased in adult asthmatics in association with the disease severity, particularly in patients with severe asthma, although the number of severe asthma patients is not enough to draw conclusion. This could be explained by significant correlations between fMLP-induced ROS production with decreased lung function, and increased bronchial hyper-reactivity to methacholine. These results are consistent with those of previous studies that found a negative correlation between lung function parameters and sputum neutrophil counts in asthmatics.[@B6][@B24] These findings demonstrate that measurement of PBN-derived ROS production may be a useful *in vitro* model for assessing the functional status of neutrophils in severe asthma.

AERD has been considered the severe form of adult-onset eosinophilic asthma, which is comorbid with chronic rhinosinusitis and nasal polyps.[@B30] Due to increased baseline levels of prostaglandin D2 and cysteinyl leukotrienes,[@B31] both eosinophils and mast cells are targeted as the major effector cells in the pathogenesis of AERD. However, little is known about the effector function of neutrophils in the airway inflammation in AERD patients. Increased neutrophil chemotactic activity in serum has been noted during early and late asthmatic response after Lys-ASA BPT in AERD patients.[@B32] The production of leukotriene B4, a chemoattractant to neutrophils, is also increased in AERD patients, similar to leukotriene E4,[@B33] which can be explained by impaired granulocyte functions leading to leukotriene B4 production.[@B12] In addition, we compared sputum inflammatory cell profiles among the 4 subtypes of AERD and found high neutrophil counts as well as eosinophils in sputum samples of subtypes 1 and 2 (having more severe clinical outcomes), suggesting that neutrophils are involved in the severity of airway inflammation in AERD.[@B34] In the present study, when we compared the functional status of PBNs between the AERD and ATA groups in an *in vitro*, more activated neutrophils were noted in the AERD group than in the ATA group (*i.e.*, the increased fold induction of ROS production after fMLP stimulation as compared to baseline). However, we could not find direct correlations between the ROS and cytokine production under stimulation with the % fall of FEV1 after Lys-ASA BPT. Taken together, these results suggest that the *in vitro* PBN stimulation model described herein may be useful for evaluating the functional status of neutrophils in AERD patients.

The functional status of neutrophils can be further examined by measurement of inflammatory cytokines and cytolytic granular enzymes released from neutrophils. IL-8 is a key cytokine in neutrophil recruitment, survival and inflammation,[@B35] and plays an important pathogenic role in airway inflammation of asthma; IL-8 levels are increased in both bronchoalveolar lavage fluid (BALF) and induced sputum of asthmatics.[@B36] Increased levels of granular enzymes, such as MMP-9 and myeloperoxidase (MPO), have also been found in the BALF and sputum of asthmatics in correlation with asthma severity.[@B37][@B38] The functional relevance of MPO seems to be similar to that of MMP-9; the levels were increased in both the BALF and sputum of asthmatics and negatively correlated with lung functions.[@B39] Neutrophil elastase (NE) may contribute to the development of asthma by inducing epithelial damage and enhancing bronchial hyper-reactivity.[@B40] Elevated NE levels have also been observed during asthma exacerbation and negatively correlated with FEV1 in asthmatics.[@B41] In the present study, we measured the pro-inflammatory cytokine (IL-8) and 3 cytolytic granular enzymes (MMP-9, MPO and NE) using the *in vitro* PBN stimulation model. Asthmatic patients showed an increased release of IL-8 and MMP-9 under stimulation. However, we failed to measure MPO and NE because the baseline level of MPO was too high to compare, while the baseline level of NE was less than the detection limit, therefore, they were excluded in comparisons. The expression of CD11b, a neutrophil activation marker, was also increased under stimulation, although the number of study subjects was limited. These findings suggest that measurement of IL-8 and MMP-9 released from PBNs are practical parameters to evaluate neutrophil functions using *in vitro* stimulation models.

The functional status of neutrophils could also be used for evaluating therapeutic potential of neutrophil-targeting candidates. In this study, FTY720 was targeted due to its antagonizing effect on S1P signaling, which may represent a novel therapeutic candidate for the management of asthma.[@B13][@B14][@B15] S1P signaling can directly effect on neutrophil functions via S1P receptor type 1 (S1PR1)-mediated ROS generation under fMLP stimulation.[@B17] Previously, we reported an altered sphingolipid metabolic pathway in AERD (*i.e.*, increased serum level of S1P during Lys-ASA BPT in AERD patients).[@B42] Therefore, we hypothesized that the inhibitory action of FTY720 on S1P signaling could be a biological target for controlling neutrophilic inflammation to attenuate neutrophil activation in asthmatics. In the present study, when we examined the therapeutic potential of FTY720 using the *in vitro* PBN stimulation model, the activated status of neutrophils was decreased significantly by FTY720 in the aspects of ROS production, CD11b expression, and IL-8/MMP-9 release. These findings suggest that FTY720 may modulate neutrophilic airway inflammation by reducing ROS production and inflammatory cytokine/cytolytic granular enzyme release. In addition, when we compared the clinical features between responders and non-responders to FTY 720 treatment, a favorable response was suggested in patients with higher sputum neutrophil counts. These inhibitory actions of FTY720 on ROS production seem more prominent in patients with AERD. Degree of increment of ROS production under fMLP stimulation was significantly decreased with FTY720 treatment. Taken together, these results suggest that modulation of ROS production is the major anti-inflammatory mechanism of FTY720 on activated neutrophils in asthmatic airway. Further interventions are essential to evaluate whether FTY720 may serve as a therapeutic option for patients with severe asthma or AERD.

The present study has limitations. First, we used neutrophil-enriched granulocytes with cell purity \> 95% for examination of the functional status of neutrophils; however, this mixture may contain eosinophils (especially in atopic asthmatics). Mixed populations of eosinophils and neutrophils may have different *in-vitro* characteristics than pure neutrophils. Secondly, we could not detect NE, within 1 hour of stimulation, a biomarker to represent the effector functions of neutrophil enhancing epithelial damage and bronchial hyper-reactivity. Despite the limitation, ROS measurement after 1 hour stimulation would be appropriate for clinical utility. Thirdly, the detail signaling mechanism of FTY720 on the neutrophil function was not fully examined. Further studies are required to better understand the therapeutic effects of FTY720 on neutrophilic inflammation in asthmatics.

In conclusion, this study demonstrated that the activated status of neutrophils in adult asthmatics, particularly in severe asthma and AERD. The *in vitro* PBN stimulation model described herein may be useful for assessing the functional status of neutrophils, predicting the severity of airway inflammation, and screening potential therapeutics for asthmatic patients.
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SUPPLEMENTARY MATERIALS
=======================

###### Supplementary Table S1

Peripheral blood neutrophil-derived reactive oxygen species production under stimulation according to asthma control status

###### Supplementary Table S2

The degree of increment of ROS production (ROS in a stimulated neutrophil status − ROS in a baseline neutrophil status) according to AERD
